Gamipaidok-san Possesses Antiallergic and Anti-inflammatory Activities

  • Kim Dae-Nam (Department of Pathology, College of Oriental Medicine, Daejeon University) ;
  • Kim Ji-Young (Department of Pharmacy, College of Pharmacy, Chosun University) ;
  • Han Eun-Hee (Department of Pharmacy, College of Pharmacy, Chosun University) ;
  • Oh Kyo-Nyeo (Department of Pharmacy, College of Pharmacy, Chosun University) ;
  • Kim Sung-Hoon (Department of Oncology, Graduate School of East-West Medical Science) ;
  • Jin Mi-Rim (Department of Pathology, College of Oriental Medicine, Daejeon University) ;
  • Jeong Hye-Gwang (Department of Pharmacy, College of Pharmacy, Chosun University) ;
  • Kim Dong-Hee (Department of Pathology, College of Oriental Medicine, Daejeon University)
  • Published : 2005.12.01

Abstract

Gamipaidok-san(GPDS) is the Hyungbangpaidok-san prescription fortified with the additional ingredients known to be effective for dermatitis. So it has been used for atopic dermatitis in the clinic work actually. In this study, we investigated the effects of GPDS on in vitro and in vivo anti-allergic effect on RBL-2H3 rat basophilic leukemia Cells and on IgE-induced passive cutaneous anaphylaxis (PCA) in mice. The in vitro anti-inflammatory activity of GPDS in RAW 264.7 cells was investigated. GPDS potently inhibited $\beta$-hexosaminidase release from RBL-2H3 and the IgE-mediated PCA reaction in mice. GPDS inhibited LPS-induced NO and PGE2 production in a dose-dependent manner Furthermore, It also inhibited inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) protein expression in RAW 264.7 cells, and the activation of the transcription factor, NF-kB, in nuclear fraction. The antiallergic action of GPDS may originate from anti-inflammatory activities, and can improve the inflammation caused by allergies.

Keywords

References

  1. Baeuerle, P.A., Henkel, T. Function and activation of NF-kB in the immune system. Ann. Rev. lmmunol. 12:141-179, 1994.
  2. Bellisle, F., Blundell, J.E., Dye, L., Fantino, M., Fern, E., Fletcher, R.J., Lambert, J., Roberfroid, M., Specter, S., Westenhofer, J. and Westerterp-Plantenga, M.S. Functional food science and behaviour and psychological functions. Br. J. Nutr. 80:S173-S193, 1998.
  3. Chen, F., Kuhn, D.C., Sun, S.C., Gaydos, L.J. and Demers, L.M. Dependence and reversal of nitric oxide production on NF-KB in silica and lipopolysaccharide induced macrophages, Biochem. Biophys. Res. Commun. 214:839-846, 1995.
  4. Chomczynski, P. and Sacchi, N. Single-step method of RNAisolation by acid guanidinium thiocyanate-phenolchloroform extraction. Anal. Biochem, 162:156-159, 1987.
  5. D'Acquisto, F., Iuvone. T., Rombola, L., Sautebin, L., Rosa, M.D. and Carnuccio, R. Involvement of NF-kappaB in the regulation of cyclooxygenase-2 protein expression in LPSstimulated J774 macrophages. FEBS Lett. 418:175-178, 1997.
  6. Hofseth, L.J., Hussain, S.P. Wogan, G.N. and Harris, C.C. Nitric oxide in cancer and chemoprevention. Free Radic. Biol Med. 34:955-968, 2003.
  7. Inoue, H., Urnesono, K., Nishimori, T., Hirata, Y. and Tanabe, T. Glucocorticoid-mediated suppression of the promoter activity of the cyclooxygenase-2 gene is modulated by expression of its receptor in vascular endothelial cells. Biochem, Biophys. Res. Commun. 254:292-298, 1997.
  8. Jeong, H.G. and Kim, J.Y. Induction of inducible nitric oxide synthase expression by 18$\beta$-glycyrrhetinic acid in macrophages. FEBS Lett. 513:208-212, 2002 .
  9. Kawamori, T., Rao, C.V., Seibert, K. and Reddy, B.S. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. 58:409-412, 1998.
  10. Kim, J.Y., Oh, K.N., Han, E.H., Kim, D.H, Jeong, T.C., Lee, E.S. and Jeong, H.G. Methoxychlor-induced inducible nitric oxide synthase and proinflammatory cytokines expression in macrophages via NF-kappaB, ERK, and p38 mitogen-activated protein kinases. Biochem, Biophys. Res. Commun. 333:1234-1240.
  11. Knoops. L., Louahed, J., Van Snick, J. and Renauld, J.C. IL-9 promotes but is not necessary for systemic anaphylaxis. J. Immunol. 175: 335-341.
  12. Laughter, D., Istvan, J.A, Tofte, S.J. and Hanifin, J.H The prevalence of atopic dermatitis in Oregon schoolchildren. J. Am. Acad. Dermatol. 43:649-655, 2000.
  13. Leung, D.Y.M. Atopic dermatitis: new insights and opportunities for therapeutic intervention. J. Allergy Gin. lmmunol. 105:860-876, 2000.
  14. MacMicking, J., Xie, Q.W. and Nathan, C. Nitric oxide and macrophage function. Annu. Rev. Immunol. 15:323-350, 1997.
  15. Maeda, H. and Akaike, T. Nitric oxide and oxygen radicals in infection, inflammation, and cancer. Biochemistry. 63:854-865, 1998.
  16. Mayer, B. and Hemmens, B. Biosynthesis and action of nitric oxide in mammalian cells. Trends Biochem. Sci. 22:477-481, 1997.
  17. Mitchell, J.A, Larkin, S. and Williams, T.J. Cyclooxygenase 2: regulation and relevance in inflammation. Biochem. Pharmacal. 50:1535-1542, 1995.
  18. Ristimaki, A., Honkanen, N., Jankala, H., Sipponen, P., Harkonen, M. Expression of cyclooxygenase-2 ·in human gastric carcinoma. Cancer Res. 57:1276-1280, 1997.
  19. Roshak, A.K., Jackson, J.R, CMGough, K., Chabot-Fletcher, M., Mochan, E. and Marshall, L.A Manipulation of distinct NF-KB proteins alters interleukin-1$\beta$-induced human rheumatoid synovial fibroblast prostaglandin E2 formation, J. BioI. Chem. 271:31496-31501, 1996.
  20. Schultz-Larsen, F., Diepgen, T. and Svensson, A .The occurrence of atopic dermatitis in north Europe: an international questionnaire study. J. Am. Acad. Dermatol. 34:760-764, 1996.
  21. Sheng, H., Shao, L Hooton, E.B., Tsujii, M., Dubois, RN. and Beauchamp, RD. Cyclooxygenase-2 induction and transforming growth factor beta growth inhibition in rat intestinal epithelial cells. Cell Growth Differ. 8:463-470, 1997.
  22. Simon, L.S. Role and regulation of cyclooxygenase-2 during inflammation. Am. J. Med. 106:375-425, 1999.
  23. Smith, W.L., DeWitt, D.L., Caravito, RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem. 69:145-182, 2000.
  24. Subbaramaiah, K. and Dannenberg, A,J. Cyclooxygenase 2; a molecular target for cancer prevention and treatment. Trends. Pharmacal. Science. 24:96-102, 2003.
  25. Tak, P.P. and Firestein. G.5. NF-kappaB: a key role in inflammatory diseases. J. Clin. Invest. 107:7-11, 2001.
  26. Xie, Q.W., Kashiwabara, Y. and Nathan, C. (Role of transcription factor NF-$\kappa$B/Rel in induction of nitric oxide synthase. J. BioI. Chem. 269:4705-4708.
  27. Zhang, M.Z., Wang, J.L., Cheng, H.F., Harris, RC. and McKanna, J.A Cyclooxygenase-2 in rat nephron development. Am. J. Physiol. 273:994-1002, 1997.